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Abstract
Background: Few have studied how personal activities of daily living (P-ADL) develop over time in nursing home
residents with dementia. Thus, the aim was to study variables associated with the development of P-ADL functioning
over a 52-month follow-up period, with a particular focus on the importance of the degree of dementia.
Method: In all, 932 nursing home residents with dementia (Clinical Dementia Rating–CDR- Scale ≥1) were included in a
longitudinal study with four assessments of P-ADL functioning during 52 months. P-ADL was measured using the
Lawton and Brody’s Physical Self-Maintenance Scale. Degree of dementia (CDR), neuropsychiatric symptoms and use of
psychotropic medication were assessed at the same four time points. Demographic information and information about
physical health was included at baseline. Linear regression models for longitudinal data were estimated.
Results: Follow-up time was positively associated with a decline in P-ADL functioning. Degree of dementia at baseline
was associated with a decline in P-ADL functioning over time. The association between degree of dementia and P-ADL
functioning was strongest at baseline, and then flattened over time. A higher level of neuropsychiatric symptoms such
as agitation and apathy and no use of anxiolytics and antidementia medication were associated with a decline in
P-ADL functioning at four time points. Higher physical co-morbidity at baseline was associated with a decline in
P-ADL functioning.
Conclusion: P-ADL functioning in nursing home patients with dementia worsened over time. The worsening was
associated with more severe dementia, higher physical comorbidity, agitation, apathy and no use of anxiolytics
and antidementia medication. Clinicians should pay attention to these variables (associates) in order to help the
nursing home residents with dementia to maintain their level of functioning for as long as possible.
Background
Dementia is, in most cases, characterized by a progres-
sive decline in cognitive function. In Europe, it is esti-
mated that between six to ten million persons have
dementia [1]. The prevalence of dementia increases with
age, from approximately 1.5% in persons aged 60–
69 years to 40% in persons 90 years and older [2]. The
prevalence of dementia is found to be high in nursing
home residents in the Western countries [3-6]. Studies
in Norway have indicated that more than 80% of nursing
home residents have dementia [7,8].
In general, dementia will negatively affect the person’s
ability both to function adequately in everyday life and
to perform personal activities of daily living (P-ADL),
such as bathing, dressing, eating, grooming, ambulation/
transferring and toileting [9-17].
Dementia and the accompanying P-ADL impairment
increase the risk of being admitted to nursing home care
[18,19] as increasing P-ADL impairment increases the
need of care. Lower P-ADL functioning increases the
burden for the patients, their family, the professional
caregivers and society as a whole [15,20,21]. Furthermore,
P-ADL impairment in older persons increases the risk of
mortality [22-25].
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Up to now, relatively few studies have explored how
P-ADL functioning changes over time in nursing home
residents with dementia [26]. An early study explored
P-ADL decline in nursing home residents without asses-
sing dementia and or cognitive impairment [22]. Others
have explored if the presence of dementia (yes/no) in
nursing home residents at baseline was important for later
P-ADL decline [23,27,28]. Diverging results were reported.
Furthermore, prospective register studies of nursing home
residents with and without dementia have studied the as-
sociation between P-ADL decline and the degree of cogni-
tive impairment with a follow-up period of three months
to one year. These studies found that a decline of P-ADL
functioning was explained by the degree of P-ADL impair-
ment and degree of cognitive impairment at baseline
[29-32]. None of the register studies explored the import-
ance of medical co-morbidity to a P-ADL decline.
A recent six-month follow-up study of long-term resi-
dents with dementia reported that a decline in P-ADL
functioning was associated with the patients’ degree of
dementia [26]. However, this study had excluded the res-
idents with physical co-morbidities and did not study
the influence of neuropsychiatric symptoms on P-ADL
development. Information about medical co-morbidity
and neuropsychiatric symptoms should be included, since
studies report that such symptoms may have importance
for P-ADL functioning [31,33,34]. Other risk factors for a
decline in P-ADL functioning over time in nursing home
residents may be age, ethnicity, gender, marital status and
education [22,27,28,31,32,35]. Protective factors for a de-
cline in P-ADL have also been reported, such as the long-
term use of antidementia medication [20,36,37].
A number of disease specific and generic P-ADL in-
dexes have been developed, validated and found sensitive
to small but significant changes in persons’ ability to
perform P-ADL [20,38]. Even so, several studies of P-
ADL decline in nursing home residents have used single
items [26,32,33,35] rather than P-ADL indexes covering a
range of P-ADL functions [23,31]. The Physical Self-
Maintenance Scale is one of the shorter recommended
P-ADL indexes [20], which has been frequently used in
Scandinavian studies [7,8,39,40].
To our knowledge no long-term follow-up of nursing
home residents has been conducted including both a
measure of cognition and physical co-morbidities. Thus,
our aim was to study the association between degree of
dementia, both at baseline and over more than four
years, and the development in P-ADL functioning mea-
sured by the Physical Self-Maintenance Scale (P-ADL
score), adjusting for a number of other variables know to
have an influence on P-ADL functioning in nursing home
residents with dementia. We hypothesize that P-ADL
functioning in persons with dementia living in nursing
homes will decline over time, and that this decline will
be associated with a worsening of dementia, the neuro-




This was a 52 months prospective study with four assess-
ments. Baseline assessment took place between November
2004 and January 2005. The follow-up assessments took
place after 12, 31 and 52 months.
Participants
All residents in 26 nursing homes in 18 municipalities
and four counties in Norway with a stay of a minimum
of 14 days were asked to participate in the study. The
municipalities were chosen to make the sample repre-
sentative in terms of municipality size [8]. In all, 1165
residents were eligible. Two residents or their next of
kin refused participation, four had important missing in-
formation, and 233 had no dementia according to the
Clinical Dementia Rating (CDR) scale, i.e. CDR < 1 [41].
Thus, 932 residents were included in the longitudinal
study of P-ADL.
Measures
The Demographic information age, level of education,
marital status and length of stay at inclusion, was col-
lected from the medical records.
The Medical health information was collected from
the medical records with the use of diagnoses in the
International Statistical Classification of Diseases and
Related Health problems 10th Revision (ICD-10). The
diagnoses were sorted into diagnostic groups, i.e. stroke-,
cardiovascular-, pulmonary-, musculoskeletal-, digestive-,
endocrine-, neurological-, genito-urinal- and neoplasm
diagnoses [42]. A co-morbidity index was calculated by
summing up the occurrence of diagnoses (yes/no) in each
of the nine groups of diagnoses.
Sensory loss was registered by two single items for vi-
sion and hearing impairment, respectively, i.e. perceived
severely impaired or not. No specific measurement was
used and the occurrence of vision and hearing impair-
ment are based on the primary professional caregiver’s
clinical judgement.
Dementia was assessed using the Clinical Dementia
Rating (CDR) scale which covers six domains (memory,
orientation, judgment and problem solving, community
affairs, home and hobbies, and personal care) with five
response categories (0, 0.5, 1, 2, 3) [41,43]. The total
score is calculated by means of an algorithm giving pri-
ority to memory [41]. Residents with a total score of one
or higher were regarded as having dementia [44-46]. In
the analysis we used the CDR sum score (sum of boxes),
which ranges from 0 to 18 with a higher score indicating
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greater dementia severity. The correlation between the
CDR score and the CDR sum of boxes is high. However,
due to an increased range of values, the CDR sum of boxes
offers important advantages when analyzing the data. [47].
Neuropsychiatric symptoms were assessed using the
Neuropsychiatric Inventory (12-item NPI) [48] in a trans-
lated and validated Norwegian version [49]. The 12-item
inventory covers the following symptoms: delusion, hallu-
cination, agitation/aggression, disinhibition, irritability/
lability, depression/dysphoria, anxiety, apathy/indifference,
aberrant motor behaviour, sleep and night-time behaviour
disorder and appetite/eating changes. For each symptom,
severity (score 1–3) multiplied by frequency (score 1–4)
gave a score ranging from one to twelve. Based on a previ-
ous principal component analysis, psychosis (delusions,
hallucination), agitation (agitation/aggression, disinhib-
ition, irritability) and affective (depression, anxiety) sub-
syndrome scores were formed by summing the score of
the included items [50-53].
Psychotropic medications were grouped according to
the ATC code, into antipsychotics (N05A except lithium),
antidepressants (N06A), anxiolytics (N05B), hypnotics/
sedatives (N05C) and antidementia medication (N06D)
(yes versus no). The information was collected from the
medical record of each resident.
Level of functioning in personal Activities of Daily
Living (P-ADL), the dependent variable, was measured
by the Physical Self-Maintenance Scale (six items, score
range 6–30, i.e. P-ADL scale score) [54]. High scores in-
dicate a lower level of functioning.
Procedure
Prior to the study, 16 research assistants (all registered
nurses) attended a two-day training program on how to
conduct the interview. A one-day training program was
carried out prior to each follow-up assessment. The pro-
ject leader (GS) was available for consultation while the
data were collected. The research assistants collected the
data by means of a standardized interview with the pri-
mary professional caregiver and by extracting informa-
tion from the medical records.
Study information was given to the patient and their
family members. An explicit consent was not required
for enrollment, but the patients and their next of kin
were informed in writing that they could refuse to par-
ticipate at any stage of the study. The study, and the
procedure for information and the right to decline par-
ticipation were approved by the Regional Ethics Com-
mittee of Eastern Norway in 2004, the Data Inspectorate
and the Directorate for Health and Social Affairs.
Data analysis
Continuous socio-demographic and clinical characteristics
were presented as means and standard deviations (SD),
while frequencies and proportions were used for categor-
ical characteristics. A linear regression model was esti-
mated to assess the development in P-ADL throughout the
follow-up period of 52 months. As P-ADL consists of re-
peated measurements, the assumption of independent ob-
servations required for ordinary linear regression was
violated. Therefore, a linear mixed model containing both
linear and second–order time components as fixed effects
(growth model) as well as random effects for intercepts
and slopes for time was estimated first. Such a model ac-
counts for correlations due to repeated measurements and
accommodates any degree of imbalance in longitudinal
data. That is, the model is particularly suited for analysing
data with missing values and drop-outs due to death, for
instance. The SAS MIXED procedure was used to fit the
model. The main independent variable, degree of dementia
assessed with CDR sum of boxes, and interaction term
between degree of dementia and time were then entered
into the model as fixed effects. Two different models with
Table 1 Characteristics of study sample at baseline
(N=932)
Demographic Total
Previous length of stay (days) Mean (SD) 928.9 (910.1)
Women N (%) 686 (73.6)
Age (year) Mean (SD) 84.5 (7.5)
Single as marital status N (%) 714 (79.4)
Ten years of school or less N (%) 673 (74.1)
Information on somatic health
Co-morbidity index1 Mean (SD) 1.8 (1.3)
Severely impaired hearing N (%) 126 (13.6)
Severely impaired vision N (%) 139 (14.9)
Cognitive functioning
CDR sum of boxes Mean (SD) 13.1 (4.0)
Behavioral and psychological sub-syndromes
of dementia (12-item NPI)
Agitation Mean (SD) 6.5 (8.2)
Psychosis Mean (SD) 3.2 (5.4)
Affective Mean (SD) 3.7 (5.4)
Apathy Mean (SD) 2.4 (3.8)
Psychotropic medication2
Antipsychotics N (%) 241 (25.9)
Antidepressants N (%) 364 (39.1)
Anxiolytics N (%) 221 (23.7)
Sedatives N (%) 245 (26.3)
Antidementia N (%) 126 (13.5)
CDR= Clinical Dementia Rating Scale.
1The co-morbidity index was calculated by summing up the occurrence of
diagnoses (yes/no) in nine groups of diagnoses.
2The cumulative proportion of psychotropic medication is higher than 100 due
to combinational use of psychotropic medication.
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respect to adjustment were further estimated. In both
models, adjustment variables were demographic character-
istics (length of stay prior to baseline, age, gender, edu-
cation, and marital status), physical health information
(co-morbidity index, severe sensory loss), neuropsychiatric
symptoms and use of psychotropic medications. Length of
stay, age, and gender were defined to be the confounders,
while the other adjustment variables were defined as sec-
ondary independent variables. The first model contained
adjustment variables all measured at baseline. The second
model included demographic characteristics, somatic
health difficulties at baseline, while neuropsychiatric symp-
toms of dementia and use of psychotropic medications
were entered as longitudinal variables. The following mod-
elling strategy was employed. Firstly, a model containing
all defined secondary independent variables was reduced
by applying Akaike’s Information Criteria (AIC). The least
significant secondary independent variables were removed
from the model one at a time and AIC was calculated at
each step. The model with the smallest value of AIC was
chosen. Secondly, the CDR sum of boxes, interaction term
between the CDR sum of boxes and time, and the three
confounders were entered into the reduced model and a
final model was estimated. Lastly, to assess eventual
gender-specific differences, interactions between gender
and CDR sum of boxes, age, and education were entered
into the final model. However, none of them were signifi-
cant and therefore excluded. The results of the regression
analysis were tabulated as coefficients with the correspond-
ing 95% confidence intervals (CI). Regression coefficients
were used to estimate the P-ADL score for each time point
from an unadjusted model as well as from both adjusted
models at the median baseline CDR sum of boxes value
and were presented graphically.
Analyses were performed in SAS v9.2 and SPSS v20.
P-values below 0.05 were considered statistically signifi-
cant. All tests were two-sided.
Results
Sample characteristics
At baseline, the mean (SD) age and length of stay for the
participants were 84.5 (7.5) years and 932 (910.1) days,
Patients with dementia included at 
T1 (n=932)
Not analyzed due to important missing information (n=2)
Death (n=142) 
Moving to another level of care (n=5)
Death (n=315) 
Moving to another level of care (n=9)
Death (n=288) 
Moving to another level of care (n=12)
T2 (n=632)
354 days (SD 16)
Not analyzed due to important missing information (n=8)
T3 (n=308)
935 days (SD 37) 
Not analyzed due to important missing information (n=12)
T4 (n=160)
1580 days (SD 43)
Not analyzed due to important missing information (n=1)
Figure 1 Flow chart of participants from baseline (T1) to last follow-up up (T4), with mean (SD) follow-up time at each assessment.
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respectively (see Table 1). In all, 246 (26.4%) of the resi-
dents were men and the mean score of the co-morbidity
index was 1.8 (SD 1.3, ranging from 0 to 6 groups of
diagnoses). The mean (SD) baseline CDR sum of boxes
was 13.1 (4.0). Of the 932 participants at baseline, 160
(17.2%) participants were available at the fourth follow-up
(see Figure 1). The individual development of P-ADL
throughout the follow-up period and the mean P-ADL at
four time points (see Table 2) indicated worsening in
P-ADL functioning, which was confirmed by the second-
order growth model. The positive linear time component
(95% CI) of 0.14 (0.12; 0.16) shows that the P-ADL func-
tioning declined over time, and negative second-order time
component of -0.001 (-0.001: -0.0005) shows that the mean
rate of decline decreased with time.
The importance of degree of dementia for P-ADL
functioning
The importance of degree of dementia for P-ADL func-
tioning over time was studied in two adjusted models. In
Table 2 P-ADL score at four time points
Time point Min, Max Mean (SD)
T1 6, 29 18.8 (5.3)
T2 7, 30 19.6 (5.2)
T3 7, 30 20.8 (4.8)
T4 9, 29 21.6 (4.6)
Table 3 Model 1: Effects of cognitive impairment (CDR sum of boxes) measured at baseline on P-ADL level over time
estimated by linear mixed model with random effects for intercepts and time
In dependent variables
Unadjusted regression coefficients Adjusted regression coefficients
Coeff. (95% CI) p-value Coeff. (95% CI) p-value
Effect of main variables1
Time 0.19 (0.15; 0.24) <0.001 0.20 (0.16; 0.25) <0.001
Time* time -0.001 (-0.001; -0.0005) <0.001 -0.001 (-0.002; -0.001) <0.001
CDR sum of boxes 0.72 (0.65; 0.79) <0.001 0.61 (0.53; 0.69) <0.001
Time* CDR sum of boxes -0.004 (-0.007; -0.001) 0.007 -0.004 (-0.007; -0.001) 0.013
Effect of additional variables at baseline2
Length of stay 0.002 (0.001; 0.002) <0.001 0.001 (0.001; 0.001) <0.001
Socio –demographic information
Age (years) -0.02 (-0.06; 0.02) 0.312 -0.05 (-0.09; -0.01) 0.007
Women -0.33 (-1.03; 0.38) 0.362 -0.62 (-1.25; 0.01) 0.054
Single -0.80 (-1.58; -0.03) 0.042 -0.72 (-1.41; -0.03) 0.041
Ten years of education or less 0.46 (-0.25; 1.17) 0.206 0.48 (-0.12; 1.07) 0.117
Somatic health difficulties
Co-morbidity index 0.21 (-0.04; 0.46) 0.100 0.32 (0.11; 0.53) 0.003
No severe vision impairment 1.65 (0.77; 2.53) <0.001 0.93 (0.19; 1.67) 0.014
No severe hearing impairment -0.79 (-1.70; 0.13) 0.091 -0.12 (-0.90; 0.66) 0.765
Degree of neuropsychiatric problems
Agitation sub-syndrome 0.08 (0.04; 0.12) <0.001 0.01 (-0.0; 0.04) 0.546
Psychosis sub- syndrome 0.04 (-0.02; 0.10) 0.150
Affective sub-syndrome 0.02 (-0.04; 0.07) 0.602
Apathy 0.35 (0.27; 0.43) <0.001 0.10 (0.03; 0.18) 0.007
Use of psychotropic medication
Antipsychotics 0.72 (0.01; 1.42) 0.046 -0.08 (-0.69; 0.53) 0.802
Antidepressants -0.56 (-1.19; 0.07) 0.081 -0.33 (-0.86; 0.20) 0.225
Anxiolytics -0.28 (-1.01; 0.44) 0.443 -0.70 (-1.31; -0.10) 0.024
Sedatives -0.65 (-1.36; 0.05) 0.070 -0.12 (-0.70; 0.47) 0.701
Cognitive enhancers -3.23 (-4.09; -2.36) <0.001 -1.81 (-2.58; -1.05) <0.001
1The coefficients of the main effect variables (time, squared time, CDR sum of boxes, and interaction between time and CDR sum of boxes) unadjusted for other
independent variables.
2The coefficients (95%CI) for single independent variables from the model containing only linear and second-order time components.
* = Multiplied with Bold data indicate p-value <0.05.
Helvik et al. BMC Geriatrics 2014, 14:45 Page 5 of 10
http://www.biomedcentral.com/1471-2318/14/45
the first adjusted model (Table 3), the association be-
tween degree of dementia at baseline and P-ADL func-
tioning over time was assessed. There was a significant
second-order time trend in P-ADL functioning, and
more severe dementia at baseline was associated with
declined P-ADL functioning over time. The association
between degree of dementia and P-ADL functioning was
strongest at baseline, the development in time flattened
and the association between the baseline degree of de-
mentia and the decline in P-ADL functioning decreased
with time.
Table 4 presents the results from the second model
finding degree of dementia at each time point being
associated with poorer P-ADL functioning at the same
time points. As in the first model, there was a decline in
P-ADL functioning throughout the follow-up period.
Furthermore, as in the first model, the association be-
tween degree of dementia and P-ADL functioning was
strongest at baseline, the development in time flattened
and the association between baseline degree of dementia
on decline in P-ADL functioning became weaker with
time.
In addition, longer length of stay, being married, hav-
ing a higher comorbidity index score and having se-
verely impaired vision at baseline were associated with
worse P-ADL functioning through the observation period.
Table 4 Model 2: Effects of cognitive impairment (CDR sum of boxes) measured at four time points on P-ADL level at
the same time points estimated by linear mixed model with random effects for intercepts and time
Unadjusted regression coefficients Adjusted regression coefficients
Coeff. (95% CI) p-value Coeff. (95% CI) p-value
Effect of main variables1
Time 0.06 (0.02; 0.10) 0.002 0.18 (0.14; 0.22) <0.001
Time* time 0.001 (-0.001; -0.001) <0.001 -0.001 (-0.001; -0.0004) <0.001
CDR sum of boxes (at 4 time points) 0.48 (0.43; 0.54) <0.001 0.60 (0.52; 0.67) <0.001
Time* CDR sum of boxes 0.003 (0.001; 0.006) 0.007 -0.003 (-0.006; -0.0006) 0.019
Effect of additional variables at baseline2
Length of stay 0.002 (0.001; 0.002) <0.001 0.001 (0.001; 0.0011) <0.001
Socio –demographic information
Age (years) -0.02 (-0.06; 0.02) 0.312 -0.04 (-0.08; -0.004) 0.030
Women -0.33 (-1.03; 0.38) 0.362 -0.51 (-1.13; 0.11) 0.108
Single -0.80 (-1.58; -0.03) 0.042 -0.78 (-1.45; -0.11) 0.023
Ten years of education or less 0.46 (-0.25; 1.17) 0.206 0.45 (-0.14; 1.03) 0.136
Somatic health difficulties
Co-morbidity index 0.21 (-0.04; 0.46) 0.100 0.35 (0.15; 0.56) 0.001
No severe vision impairment 1.65 (0.77; 2.53) <0.001 0.88 (0.14; 1.61) 0.019
No severe hearing impairment -0.79 (-1.70; 0.13) 0.091 -0.16 (-0.92; 0.61) 0.689
Effect of additional variables assessed at 4 time-points2
Degree of neuropsychiatric problems
Agitation sub-syndrome 0.04 (0.02; 0.06) <0.001 0.03 (0.003; 0.05) 0.026
Psychosis sub- syndrome 0.02 (-0.01; 0.06) 0.173
Affective sub-syndrome 0.01 (-0.03; 0.04) 0.614 -0.03 (-0.06; 0.01) 0.166
Apathy 0.20 (0.15; 0.24) <0.001 0.12 (0.08; 0.17) <0.001
Use of psychotropic medication
Antipsychotics 0.77 (0.31; 1.23) 0.001 0.41 (-0.03; 0.86) 0.067
Antidepressants -0.63 (-1.05; -0.20) 0.004 -0.40 (-0.80; 0.003) 0.052
Anxiolytics -0.67 (-1.15; -0.20) 0.005 -0.77 (-1.22; -0.32) 0.001
Sedatives -0.29 (-0.75; 0.17) 0.213
Cognitive enhancers -2.31 (-2.94; -1.67) <0.001 -1.72 (-2.33; -1.11) <0.001
1The coefficients of the main effect variables (time, squared time, CDR sum of boxes, and interaction between time and CDR sum of boxes) unadjusted for other
independent variables.
2The coefficients (95%CI) for single independent variables from the model containing only linear and second-order time components.
* = Multiplied with Bold data indicate p-value <0.05.
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Among the independent variables with assessments at all
four time points included in the analysis, a higher agitation
sub-syndrome score and apathy score, as well as not using
anxiolytics and antidementia medication were associated
with lower P-ADL functioning at the same time points.
Figure 2 illustrates the unadjusted P-ADL develop-
ment over the follow-up period as well as P-ADL devel-
opment adjusted in two different ways (two models).
Independently of the adjustments made, there is an
upward trend in the P-ADL values over time, i.e. the
P-ADL functioning declines, but the rate of decline
flattened during follow-up. The degree of decline in
P-ADL functioning during follow-up was moderated using
the adjusted models.
Discussion
This follow-up study of 932 nursing home residents with
dementia found that degree of dementia at baseline and
the course of dementia as measured by the CDR during
follow-up was significantly associated with lower P-ADL
functioning. The rate of decline in P-ADL functioning
explained by the degree of dementia decreased during
follow-up. Independently of the adjustments made, there
is a decline in P-ADL function over time and the rate
of decline due to time of follow-up decreased during
follow-up.
Other authors have pointed to a relationship between
more severe dementia and worse P-ADL both among
older hospitalized patients [11], community dwelling
older persons [9,10] and in nursing home residents
[23,26,28]. However, few have studied the P-ADL devel-
opment and slope of development of P-ADL by time
and degree of dementia in nursing home residents with
dementia using several years of follow-up. Our results
are supported by a six month follow-up study among
residents with dementia. In this study, the mean P-ADL
reduction increased in residents with severe dementia
[26]. Another nursing home study in the USA, which
followed residents with and without dementia for one
year, explored if the degree of cognitive impairment
at baseline affected the rate of P-ADL decline during
follow-up [31]. This study with a follow-up period of
12 months did not find that cognitive impairment at
baseline affected the rate of decline in P-ADL function-
ing over time, but a low P-ADL functioning at baseline
was explained by baseline cognition [31]. However, a
recent Swedish community study of older persons diag-
nosed with minimal cognitive impairment or Alzheimer
disease reported that the rate of decline in P-ADL func-
tioning due to degree of cognitive impairment decreased
during the follow-up period of eight years, i.e. the slope
of decline in P-ADL functioning leveled off [55]. Our
results as well as the results of the Swedish study
indicate the importance of “tailoring” the care for persons
with dementia as the dementia disorder progress and the
P-ADL decrease. The tailoring of care according to the
patients increasing needs will probably increase the
quality of life for the persons with dementia [56].
Interestingly, we found that worse P-ADL functioning
at each time point was associated with a higher level of
neuropsychiatric symptoms at the same time points, i.e.
higher agitation sub-syndrome or apathy symptoms. Our
findings are in line with previous research. Previously, it
has been reported that a higher baseline sum score of
neuropsychiatric symptoms is associated with a higher
tendency for falls the coming year [33] and apathy symp-
toms have been reported to be associated with more
motor and process skills difficulties [34]. The present
study found an association between higher P-ADL func-










Unadjusted Adjusted model 1 Adjusted model 2
Figure 2 Development of P-ADL score in time, unadjusted, adjusted in Model 1 and adjusted in Model 2. P-ADL values demonstrate a
significant second-order time trend indicating that the P-ADL functioning declines at the start of the follow-up period and flattens out later.
Adjustment of time trend for clinical and demographic characteristics resulted only in minor changes.
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in line with the findings of many randomized con-
trolled trials that have shown an effect of treatment with
antidementia medication on P-ADL [20,36,37]. However,
residents using anti-dementia medication may have higher
P-ADL functioning of other reasons which we did not ad-
just for. Why the use of anxiolytics should have a positive
effect on P-ADL functioning is not easy to explain, but it
could be that by reducing anxiety in patients with demen-
tia, especially in those with agitation, their concentration
and activity can improve.
In contrast to prospective studies which have not stud-
ied the importance of physical health in nursing home
residents for the association between degree of dementia
and P-ADL functioning or have excluded residents with
co-morbid physical disorders [26,29-32], the present study
adjusted for co-morbid physical disorders. In line with pre-
vious known risk factors for the decline of P-ADL over
time, we found that higher co-morbidity and severe vision
impairment at baseline were associated with lower P-ADL
functioning at each time point [10]. This knowledge should
also be used when tailoring the care for persons with de-
mentia according to their needs.
Even if the study has a number of advantages, such
as using a well-known, internationally accepted P-ADL
measure, having a high number of baseline residents and
adjustment for a high number of variables of potential
importance to the outcome, such as health and demo-
graphic variables, there are some limitations that need
to be addressed. Firstly, associations found in our study
should be interpreted with caution since our design does
not allow for inferences about causality.
Secondly, assessments of P-ADL functioning of older
persons in a longitudinal study with several follow-ups
over a period of years are statistically challenging. Repeat-
edly measured P-ADL functioning for the same individ-
uals implies dependency in data. Having a large number of
drop-outs, due to death leads to a varying number of ob-
servations per individual and generates unbalanced longi-
tudinal data. Furthermore, a number of the independent
variables in the adjusted models are time-varying. How-
ever, the linear mixed model used is particularly flexible
with respect to these issues. The model handles any degree
of imbalance in data by including all available observations.
It also accounts for the correlations among repeated mea-
surements in a relatively parsimonious way.
Thirdly, even if information about use of each category
of psychotropic medications were available, we did not
have the dosages of the psychotropic medications. More-
over, use of a well-known comorbidity index, f. ex.
Charlson comorbidity index [57,58] rather than the comor-
bidity index we applied would have been more informative.
Lastly, it may be questioned if the Minimal Mental State
Examination [59,60] widely used and accepted could have
been a better choice for the assessment dementia than
CDR which we applied. The MMSE has the advantage
of providing a direct measure of cognition. However, in a
sample as ours many will have scores in the lower range,
and previous research has questioned the ability of the
MMSE to differentiate between persons with severe de-
mentia [61]. As a consequence of these limitations, we can-
not rule out that there are confounders which we have not
adjusted adequately for.
Conclusion
In a large-scale longitudinal nursing home study among
patients with dementia, using four assessments during a
period of 52 months, we found that P-ADL functioning
worsened over time. The worsening of P-ADL functioning
was associated with a higher baseline degree of dementia
and with an increasing degree of dementia during follow-
up. The importance of degree of dementia and follow-up
time for degree of decline in P-ADL functioning decreased
during follow-up.
Clinicians should pay attention to the associates of
P-ADL functioning identified in our study in order to help
the nursing home residents with dementia maintain their
level of functioning as long as possible.
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